» Articles » PMID: 7694153

B70 Antigen is a Second Ligand for CTLA-4 and CD28

Overview
Journal Nature
Specialty Science
Date 1993 Nov 4
PMID 7694153
Citations 214
Authors
Affiliations
Soon will be listed here.
Abstract

The membrane antigen B7/BB1 (refs 1, 2) is expressed on activated B cells, macrophages and dendritic cells, and binds to a counter-receptor, CD28, expressed on T lymphocytes and thymocytes. Interaction between CD28 and B7 results in potent costimulation of T-cell activation initiated through the CD3/T-cell receptor complex. Discrepancies between results with anti-CD28 and anti-B7 antibodies have suggested the existence of a second ligand for CD28 and CTLA-4 (refs 3, 6-8). We have generated a monoclonal antibody, IT2, that reacts with a 70K glycoprotein (B70). B70 complementary DNA was cloned from a B-lymphoblastoid cell line library and encodes a new protein of the immunoglobulin superfamily with limited homology to B7. B70 is expressed on resting monocytes and dendritic cells and on activated, but not resting, T, NK and B lymphocytes. IT2 substantially inhibited the binding of a CTLA4-immunoglobulin fusion protein to human B-lymphoblastoid cell lines and, together with anti-B7 antibody, completely blocked CTLA-4 binding. Further IT2 efficiently inhibited primary allogeneic mixed lymphocyte responses. These findings indicate that B70 is a second ligand for CD28 and CTLA-4 and may play an important role for costimulation of T cells in a primary immune response.

Citing Articles

Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy.

Hu Q, Shi Y, Wang H, Bing L, Xu Z Exp Hematol Oncol. 2025; 14(1):37.

PMID: 40087690 DOI: 10.1186/s40164-025-00627-6.


Dysfunction and regulatory interplay of T and B cells in chronic hepatitis B: immunotherapy and emerging antiviral strategies.

Yu F, Zhu Y, Li S, Hao L, Li N, Ye F Front Cell Infect Microbiol. 2024; 14:1488527.

PMID: 39717542 PMC: 11663751. DOI: 10.3389/fcimb.2024.1488527.


Belatacept and regulatory T cells in transplantation: synergistic strategies for immune tolerance and graft survival.

Kim G, Nam K, Choi J Clin Transplant Res. 2024; 38(4):326-340.

PMID: 39690903 PMC: 11732762. DOI: 10.4285/ctr.24.0057.


Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages.

Li Y, Chen Y, Meng Y, Shen M, Yang F, Ren X Cancer Biol Med. 2024; 21(12.

PMID: 39651787 PMC: 11745090. DOI: 10.20892/j.issn.2095-3941.2024.0269.


Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors.

Barcia Duran J, Das D, Gildea M, Amadori L, Gourvest M, Kaur R Nat Cardiovasc Res. 2024; 3(12):1482-1502.

PMID: 39613875 PMC: 11634783. DOI: 10.1038/s44161-024-00563-4.